Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GTB 5550

Drug Profile

GTB 5550

Alternative Names: B7H3 TriKE™; cam1615B7H3; GTB-5550; GTB-5550 TriKE™

Latest Information Update: 03 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Minnesota
  • Developer GT Biopharma
  • Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Interleukins; Recombinant fusion proteins; Single-domain antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 15 replacements; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple myeloma; Solid tumours

Most Recent Events

  • 06 May 2024 GT Biopharma plans a phase I dose escalation basket trial trial for GBT 5550 in Solid tumours in 2025
  • 26 Mar 2024 GT Biopharma plans to file an IND application for Solid tumours including Prostate and Breast cancer in Q1 2025
  • 31 Dec 2023 GT Biopharma receives response letter from the US FDA for GTB 5550 in Solid tumours
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top